{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:44:39Z","timestamp":1786985079061,"version":"build-2736575974"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T00:00:00Z","timestamp":1626307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["W1241"],"award-info":[{"award-number":["W1241"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["DOC 31-B26"],"award-info":[{"award-number":["DOC 31-B26"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.bcp.2021.114690","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T01:59:52Z","timestamp":1626400792000},"page":"114690","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["The JAK1\/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia"],"prefix":"10.1016","volume":"192","author":[{"given":"Petra","family":"Luschnig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Kienzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Roula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Pilic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reham","family":"Atallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akos","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva M.","family":"Sturm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2021.114690_b0005","unstructured":"Global Strategy for Asthma Management and Prevention., Global Initiative for Asthma (GINA), 2021."},{"issue":"9998","key":"10.1016\/j.bcp.2021.114690_b0010","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S0140-6736(15)00157-9","article-title":"Targeting the interleukin pathway in the treatment of asthma","volume":"386","author":"Chung","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bcp.2021.114690_b0015","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.bcp.2021.114690_b0020","doi-asserted-by":"crossref","unstructured":"F.N. Schleich, A. Chevremont, V. Paulus, M. Henket, M. Manise, L. Seidel, R. Louis, Importance of concomitant local and systemic eosinophilia in uncontrolled asthma, Eur Respir J 44(1) (2014) 97-108.","DOI":"10.1183\/09031936.00201813"},{"issue":"2","key":"10.1016\/j.bcp.2021.114690_b0025","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1183\/09031936.97.10020292","article-title":"The distribution of eosinophils and lymphocytes in the large and small airways of asthmatics","volume":"10","author":"Carroll","year":"1997","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.bcp.2021.114690_b0030","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1183\/09031936.98.12051209","article-title":"Difficult asthma","volume":"12","author":"Barnes","year":"1998","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.bcp.2021.114690_b0035","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1067\/mai.2000.111307","article-title":"Pathophysiology of severe asthma","volume":"106","author":"Busse","year":"2000","journal-title":"J. Allergy Clin. Immunol."},{"issue":"5","key":"10.1016\/j.bcp.2021.114690_b0040","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1365-2222.2012.03965.x","article-title":"Severe asthma: future treatments","volume":"42","author":"O'Byrne","year":"2012","journal-title":"Clin. Exp. Allergy"},{"issue":"13","key":"10.1016\/j.bcp.2021.114690_b0045","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2021.114690_b0050","doi-asserted-by":"crossref","unstructured":"E.R. Bleecker, J.M. FitzGerald, P. Chanez, A. Papi, S.F. Weinstein, P. Barker, S. Sproule, G. Gilmartin, M. Aurivillius, V. Werkstrom, M. Goldman, S.s. investigators, Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial, Lancet 388(10056) (2016) 2115-2127.","DOI":"10.1016\/S0140-6736(16)31324-1"},{"issue":"10056","key":"10.1016\/j.bcp.2021.114690_b0055","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"C.s. investigators, Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.bcp.2021.114690_b0060","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/gb-2004-5-12-253","article-title":"The Janus kinases (Jaks)","volume":"5","author":"Yamaoka","year":"2004","journal-title":"Genome Biol."},{"issue":"11","key":"10.1016\/j.bcp.2021.114690_b0065","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/nri1226","article-title":"Regulation of JAK-STAT signalling in the immune system","volume":"3","author":"Shuai","year":"2003","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.bcp.2021.114690_b0070","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.4049\/jimmunol.178.5.2623","article-title":"The JAK-STAT signaling pathway: input and output integration","volume":"178","author":"Murray","year":"2007","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.bcp.2021.114690_b0075","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1172\/JCI0215786","article-title":"JAK-STAT signaling in asthma","volume":"109","author":"Pernis","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bcp.2021.114690_b0080","doi-asserted-by":"crossref","unstructured":"Y. Rochman, M. Kashyap, G.W. Robinson, K. Sakamoto, J. Gomez-Rodriguez, K.U. Wagner, W.J. Leonard, Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7-induced signaling, Proc Natl Acad Sci U S A 107(45) (2010) 19455-60.","DOI":"10.1073\/pnas.1008271107"},{"issue":"12","key":"10.1016\/j.bcp.2021.114690_b0085","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.2174\/13894501113149990160","article-title":"Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment","volume":"14","author":"Vuitton","year":"2013","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.bcp.2021.114690_b0090","article-title":"Olumiant\u00ae EPAR \u2013 Product","author":"Agency","year":"2017","journal-title":"Information"},{"issue":"10143","key":"10.1016\/j.bcp.2021.114690_b0095","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bcp.2021.114690_b0100","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jaad.2018.01.018","article-title":"Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study","volume":"80","author":"Guttman-Yassky","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114690_b0105","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12931-016-0436-2","article-title":"Anti-inflammatory potential of PI3Kdelta and JAK inhibitors in asthma patients","volume":"17","author":"Southworth","year":"2016","journal-title":"Respir. Res."},{"issue":"1-3","key":"10.1016\/j.bcp.2021.114690_b0110","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejphar.2007.12.024","article-title":"The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia","volume":"582","author":"Kudlacz","year":"2008","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2021.114690_b0115","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1124\/jpet.119.256263","article-title":"Novel inhaled pan-JAK inhibitor, LAS194046, reduces allergen-induced airway inflammation, late asthmatic response and pSTATs activation in Brown Norway rats","volume":"370","author":"Calbet","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"468","key":"10.1016\/j.bcp.2021.114690_b0120","doi-asserted-by":"crossref","first-page":"eaao2151","DOI":"10.1126\/scitranslmed.aao2151","article-title":"Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthma","volume":"10","author":"Dengler","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcp.2021.114690_b0125","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.3389\/fimmu.2020.01747","article-title":"Epigenetic Regulation of Airway Epithelium Immune Functions in Asthma","volume":"11","author":"Alashkar Alhamwe","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2021.114690_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2019.109523","article-title":"Role of airway epithelial cells in the development of different asthma phenotypes","volume":"69","author":"Potaczek","year":"2020","journal-title":"Cell. Signal."},{"issue":"Suppl 58","key":"10.1016\/j.bcp.2021.114690_b0135","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1183\/13993003\/erj.44.Suppl_58.3413","article-title":"Inhibition of JAK\/STAT pathway in airway epithelium as a potential targeted therapy of asthma","volume":"44","author":"Bujak","year":"2014","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.bcp.2021.114690_b0140","doi-asserted-by":"crossref","first-page":"e0128757","DOI":"10.1371\/journal.pone.0128757","article-title":"Effect of JAK Inhibitors on Release of CXCL9, CXCL10 and CXCL11 from Human Airway Epithelial Cells","volume":"10","author":"Fenwick","year":"2015","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.bcp.2021.114690_b0145","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s42003-021-02167-1","article-title":"JAK inhibitors dampen activation of interferon-stimulated transcription of ACE2 isoforms in human airway epithelial cells","volume":"4","author":"Lee","year":"2021","journal-title":"Commun Biol"},{"issue":"6","key":"10.1016\/j.bcp.2021.114690_b0150","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.4049\/jimmunol.181.6.4004","article-title":"Functionally competent eosinophils differentiated ex vivo in high purity from normal mouse bone marrow","volume":"181","author":"Dyer","year":"2008","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114690_b0155","doi-asserted-by":"crossref","first-page":"1776059","DOI":"10.1080\/2162402X.2020.1776059","article-title":"IL-33 reduces tumor growth in models of colorectal cancer with the help of eosinophils","volume":"9","author":"Kienzl","year":"2020","journal-title":"Oncoimmunology"},{"issue":"5","key":"10.1016\/j.bcp.2021.114690_b0160","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/eji.201445196","article-title":"Phosphoinositide-dependent protein kinase 1 (PDK1) mediates potent inhibitory effects on eosinophils","volume":"45","author":"Sturm","year":"2015","journal-title":"Eur. J. Immunol."},{"issue":"2","key":"10.1016\/j.bcp.2021.114690_b0165","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/all.14022","article-title":"Apolipoprotein A-IV acts as an endogenous anti-inflammatory protein and is reduced in treatment-naive allergic patients and allergen-challenged mice","volume":"75","author":"Roula","year":"2020","journal-title":"Allergy"},{"issue":"8","key":"10.1016\/j.bcp.2021.114690_b0170","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1002\/eji.201343371","article-title":"Chemotaxis of bone marrow derived eosinophils in vivo: a novel method to explore receptor-dependent trafficking in the mouse","volume":"43","author":"Sturm","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.bcp.2021.114690_b0175","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/978-1-62703-496-8_5","article-title":"Protocols for identifying, enumerating, and assessing mouse eosinophils","volume":"1032","author":"Dyer","year":"2013","journal-title":"Methods Mol. Biol."},{"issue":"1-2","key":"10.1016\/j.bcp.2021.114690_b0180","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jim.2011.04.009","article-title":"Antigen profiles for the quantitative assessment of eosinophils in mouse tissues by flow cytometry","volume":"369","author":"Dyer","year":"2011","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.bcp.2021.114690_b0185","doi-asserted-by":"crossref","unstructured":"R.B. Frei, P. Luschnig, G.P. Parzmair, M. Peinhaupt, S. Schranz, A. Fauland, C.E. Wheelock, A. Heinemann, E.M. Sturm, Cannabinoid receptor 2 augments eosinophil responsiveness and aggravates allergen-induced pulmonary inflammation in mice, Allergy 71(7) (2016) 944-56.","DOI":"10.1111\/all.12858"},{"issue":"9","key":"10.1016\/j.bcp.2021.114690_b0190","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1172\/JCI6130","article-title":"Constitutive activation of an epithelial signal transducer and activator of transcription (STAT) pathway in asthma","volume":"103","author":"Sampath","year":"1999","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.bcp.2021.114690_b0195","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.4049\/jimmunol.168.4.1978","article-title":"Lyn tyrosine kinase is important for IL-5-stimulated eosinophil differentiation","volume":"168","author":"Stafford","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2021.114690_b0200","doi-asserted-by":"crossref","unstructured":"L.X. Xia, W. Hua, Y. Jin, B.P. Tian, Z.W. Qiu, C. Zhang, L.Q. Che, H.B. Zhou, Y.F. Wu, H.Q. Huang, F. Lan, Y.H. Ke, J.J. Lee, W. Li, S.M. Ying, Z.H. Chen, H.H. Shen, Eosinophil differentiation in the bone marrow is promoted by protein tyrosine phosphatase SHP2, Cell Death Dis 7 (2016) e2175.","DOI":"10.1038\/cddis.2016.74"},{"issue":"5","key":"10.1016\/j.bcp.2021.114690_b0205","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1164\/ajrccm.160.5.9806170","article-title":"Neutrophilic inflammation in severe persistent asthma","volume":"160","author":"Jatakanon","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.bcp.2021.114690_b0210","doi-asserted-by":"crossref","unstructured":"W.C. Moore, A.T. Hastie, X. Li, H. Li, W.W. Busse, N.N. Jarjour, S.E. Wenzel, S.P. Peters, D.A. Meyers, E.R. Bleecker, L. National Heart, P. Blood Institute's Severe Asthma Research, Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis, J Allergy Clin Immunol 133(6) (2014) 1557-63.","DOI":"10.1016\/j.jaci.2013.10.011"},{"key":"10.1016\/j.bcp.2021.114690_b0215","doi-asserted-by":"crossref","unstructured":"K.J. Thorne, A.M. Glauert, R.J. Svvennsen, D. Franks, Phagocytosis and killing of Trypanosoma dionisii by human neutrophils, eosinophils and monocytes, Parasitology 79(3) (1979) 367-79.","DOI":"10.1017\/S0031182000053762"},{"issue":"6","key":"10.1016\/j.bcp.2021.114690_b0220","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/blood.V32.6.922.922","article-title":"Phagocytosis by human eosinophils","volume":"32","author":"Cline","year":"1968","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bcp.2021.114690_b0225","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1208\/s12249-019-1377-0","article-title":"Preformulation and Evaluation of Tofacitinib as a Therapeutic Treatment for Asthma","volume":"20","author":"Younis","year":"2019","journal-title":"AAPS PharmSciTech"},{"issue":"6","key":"10.1016\/j.bcp.2021.114690_b0230","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.jaci.2007.08.012","article-title":"Altered phosphorylated signal transducer and activator of transcription profile of CD4+CD161+ T cells in asthma: modulation by allergic status and oral corticosteroids","volume":"120","author":"Gernez","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114690_b0235","doi-asserted-by":"crossref","first-page":"397","DOI":"10.4049\/jimmunol.155.1.397","article-title":"The activation of the Jak-STAT 1 signaling pathway by IL-5 in eosinophils","volume":"155","author":"Pazdrak","year":"1995","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114690_b0240","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000237712","article-title":"The activation of the JAK2\/STAT5 pathway is commonly involved in signaling through the human IL-5 receptor","volume":"114","author":"Ogata","year":"1997","journal-title":"Int. Arch. Allergy Immunol."},{"issue":"6","key":"10.1016\/j.bcp.2021.114690_b0245","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/blood.V85.6.1442.bloodjournal8561442","article-title":"Interleukin-5 signaling in human eosinophils involves JAK2 tyrosine kinase and Stat1 alpha","volume":"85","author":"van der Bruggen","year":"1995","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2021.114690_b0250","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.febslet.2010.11.031","article-title":"IL-8-induced neutrophil chemotaxis is mediated by Janus kinase 3 (JAK3)","volume":"585","author":"Henkels","year":"2011","journal-title":"FEBS Lett."},{"issue":"7","key":"10.1016\/j.bcp.2021.114690_b0255","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1002\/stem.2821","article-title":"PGD2\/PTGDR2 Signaling Restricts the Self-Renewal and Tumorigenesis of Gastric Cancer","volume":"36","author":"Zhang","year":"2018","journal-title":"Stem Cells"},{"issue":"10","key":"10.1016\/j.bcp.2021.114690_b0260","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1084\/jem.20160459","article-title":"PKA regulatory IIalpha subunit is essential for PGD2-mediated resolution of inflammation","volume":"213","author":"Kong","year":"2016","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcp.2021.114690_b0265","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1051\/medsci\/201834f120","article-title":"Complement protein C5a enhances the beta-amyloid-induced neuro-inflammatory response in microglia in Alzheimer's disease","volume":"1","author":"An","year":"2018","journal-title":"Med Sci (Paris) 34 Focus issue F"},{"key":"10.1016\/j.bcp.2021.114690_b0270","doi-asserted-by":"crossref","unstructured":"M. Hurtado-Nedelec, M.J. Csillag-Grange, T. Boussetta, S.A. Belambri, M. Fay, B. Cassinat, M.A. Gougerot-Pocidalo, P.M. Dang, J. El-Benna, Increased reactive oxygen species production and p47phox phosphorylation in neutrophils from myeloproliferative disorders patients with JAK2 (V617F) mutation, Haematologica 98(10) (2013) 1517-24.","DOI":"10.3324\/haematol.2012.082560"},{"issue":"1","key":"10.1016\/j.bcp.2021.114690_b0275","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2141.2000.02103.x","article-title":"Eosinophil apoptosis: mechanisms and clinical relevance in asthmatic and allergic inflammation","volume":"111","author":"Walsh","year":"2000","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.bcp.2021.114690_b0280","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/10408369991239277","article-title":"Advances in the immunobiology of eosinophils and their role in disease","volume":"36","author":"Walsh","year":"1999","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/j.bcp.2021.114690_b0285","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000090229","article-title":"Molecules involved in the regulation of eosinophil apoptosis","volume":"91","author":"Simon","year":"2006","journal-title":"Chem. Immunol. Allergy"},{"issue":"2","key":"10.1016\/j.bcp.2021.114690_b0290","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1182\/blood.V92.2.547","article-title":"Role for tyrosine phosphorylation and Lyn tyrosine kinase in fas receptor-mediated apoptosis in eosinophils","volume":"92","author":"Simon","year":"1998","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bcp.2021.114690_b0295","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1084\/jem.188.3.421","article-title":"Lyn, Jak2, and Raf-1 kinases are critical for the antiapoptotic effect of interleukin 5, whereas only Raf-1 kinase is essential for eosinophil activation and degranulation","volume":"188","author":"Pazdrak","year":"1998","journal-title":"J. Exp. Med."},{"issue":"10","key":"10.1016\/j.bcp.2021.114690_b0300","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1136\/annrheumdis-2019-216852","article-title":"Infections in baricitinib clinical trials for patients with active rheumatoid arthritis","volume":"79","author":"Winthrop","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.bcp.2021.114690_b0305","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1136\/annrheumdis-2019-216566","article-title":"Long-term effectiveness of live herpes zoster vaccine in patients with rheumatoid arthritis subsequently treated with tofacitinib","volume":"79","author":"Winthrop","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2021.114690_b0310","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1038\/s41598-017-07261-1","article-title":"A study on the risk of fungal infection with tofacitinib (CP-690550), a novel oral agent for rheumatoid arthritis","volume":"7","author":"Chen","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2021.114690_b0315","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fphar.2017.00082","article-title":"Investigation into the Role of PI3K and JAK3 Kinase Inhibitors in Murine Models of Asthma","volume":"8","author":"Wagh","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114690_b0320","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.bbrc.2010.11.104","article-title":"Effects of a Janus kinase inhibitor, pyridone 6, on airway responses in a murine model of asthma","volume":"404","author":"Matsunaga","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221003038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221003038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:59:41Z","timestamp":1777377581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295221003038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":64,"alternative-id":["S0006295221003038"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114690","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The JAK1\/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114690","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"114690"}}